Source:http://linkedlifedata.com/resource/pubmed/id/15104675
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2004-4-23
|
pubmed:abstractText |
The promyelocytic leukemia (PML) protein is the product of the PML gene that fuses with the retinoic acid receptor-alpha (RARalpha) gene in acute promyelocytic leukemia (APL) and produces disruption of PML bodies. Wild-type PML localizes in the nucleus with a typical speckled pattern. PML bodies accumulate several proteins involved in multiple cellular pathways such as apoptosis, transcriptional regulation, and proteasomal degradation of ubiquitinated proteins. The ubiquitin-proteasome pathway at PML bodies is dependent on proteasome component recruitment. Proteasome components such as low-molecular weight proteins (LMPs) are frequently downregulated in different tumor tissues that present impaired major histocompatibility complex (MHC) class I expression. We have recently documented LMP7 downregulation in colorectal tumors with total loss of MHC class I antigen. An immunohistochemical study of PML protein in these tumors revealed a disrupted pattern of PML bodies in a nuclear diffuse form, as observed in APL cells. Therefore, the disruption of the PML bodies was clearly associated with LMP7 downregulation.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Histocompatibility Antigens Class I,
http://linkedlifedata.com/resource/pubmed/chemical/LMP7 protein,
http://linkedlifedata.com/resource/pubmed/chemical/Multienzyme Complexes,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Nuclear Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/PML protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Proteasome Endopeptidase Complex,
http://linkedlifedata.com/resource/pubmed/chemical/Transcription Factors,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Proteins
|
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0001-2815
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
63
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
446-52
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:15104675-Colorectal Neoplasms,
pubmed-meshheading:15104675-Down-Regulation,
pubmed-meshheading:15104675-Histocompatibility Antigens Class I,
pubmed-meshheading:15104675-Humans,
pubmed-meshheading:15104675-Immunohistochemistry,
pubmed-meshheading:15104675-Multienzyme Complexes,
pubmed-meshheading:15104675-Neoplasm Proteins,
pubmed-meshheading:15104675-Nuclear Proteins,
pubmed-meshheading:15104675-Proteasome Endopeptidase Complex,
pubmed-meshheading:15104675-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:15104675-Transcription Factors,
pubmed-meshheading:15104675-Tumor Suppressor Proteins
|
pubmed:year |
2004
|
pubmed:articleTitle |
Promyelocytic leukemia (PML) nuclear bodies are disorganized in colorectal tumors with total loss of major histocompatibility complex class I expression and LMP7 downregulation.
|
pubmed:affiliation |
Departamento de Análisis Clínicos, Hospital Universitario Virgen de las Nieves, Avd. Fuerzas Armadas 2, 18014 Granada, Spain.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|